RxDoctor Payments DataLook up a doctor →

David Friedman, MD

Hematology · San Antonio, TXNPI 1477526895

Payments from drug & device makers

$62,124in general payments, 2019–2025

Across 485 payments — averaging $128.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$42K
  • AstraZeneca$9K
  • Eli Lilly$3K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$945
  • Amgen$568
  • plus $5K from 45 others
$6,178in research payments, 2019–2025

Across 2 payments — averaging $3088.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$6K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.22$42,048
AstraZeneca(2 entities)53$9,347
Eli Lilly2$2,755
Novartis61$1,077
E.r. Squibb & Sons, L.L.C.60$945
Amgen20$568
Sanofi17$429
Johnson & Johnson(3 entities)20$427
Genentech USA, Inc.26$422
Merck26$417
Incyte Corporation17$299
AbbVie7$297
Regeneron Healthcare Solutions, Inc.8$243
Lilly USA, LLC10$239
Bayer7$217
Bristol Myers Squibb10$182
Gilead4$162
Pfizer29$157
GSK8$153
Astellas Pharma US Inc13$143
Caris MPI, Inc.1$137
Genmab U.S., Inc.1$125
G1 Therapeutics, Inc.1$125
Agios Pharmaceuticals, Inc.1$122
Boehringer Ingelheim8$111
Jazz Pharmaceuticals Inc.5$95
Tesaro, Inc.1$88
Seagen Inc.6$83
AVEO Pharmaceuticals, Inc.3$64
Daiichi Sankyo Inc.4$62
Tersera Therapeutics LLC2$44
Puma Biotechnology, Inc.3$42
Exelixis Inc.2$39
Array Biopharma Inc2$39
Helsinn Therapeutics (U.S.), Inc.2$38
Ipsen Biopharmaceuticals, Inc2$38
Sobi, Inc2$37
Taiho Oncology, Inc.2$37
Acrotech Biopharma Inc.1$36
Eisai Inc.2$32
EMD Serono, Inc.2$30
Rigel Pharmaceuticals, Inc.2$25
AMAG Pharmaceuticals, Inc.2$25
Sanofi-aventis U.S. LLC1$20
Tactile Systems Technology Inc1$17
Boston Scientific1$15
Medtronic1$15
Alnylam Pharmaceuticals Inc.1$15
Tempus AI, Inc1$14
Kyowa Kirin, Inc.1$14
Clovis Oncology, Inc.1$14

How this compares

$62,124 in reported general payments places this provider in the 70th percentile of 97 hematology providers in Texas.

See all hematology providers in Texas →

Medicare billing

Part B allowed, 2024
$2,472,427
Medicare patients
614
Services billed
107,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in San Antonio

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →